Streetbeat News

Products Services

F

Ford Motor Co (NYSE:F) has announced price cuts for its F-150 Lightning truck due to increased plant capacity, improved raw material costs for batteries, and continued work on scaling production. The price cuts range from $6,000 to $9,979 across different models. The company is set to report Q2 financial results on July 27, with earnings of 53 cents per share on quarterly revenue of $40.06 billion expected. Ford shares were down 1.13% at $14.81 at the time of publication.

Portfolio Pulse from Adam Eckert

July 17, 2023 | 12:58 pm

ETHUSD

Blockchain network Gnosis, an Ethereum sidechain, has launched Gnosis Pay and Gnosis Card, integrating cryptocurrency with traditional payment systems. Gnosis Pay allows web3 developers to integrate with traditional payment schemes, including Visa. Gnosis Card is a Visa-certified self-custodial consumer debit card connected to an on-chain self-custodial wallet. The card allows purchases anywhere Visa is accepted. The company aims to bridge the gap between on-chain and off-chain worlds and plans to expand to the U.S., Brazil, Mexico, Singapore, and Hong Kong.

Portfolio Pulse from Murtuza Merchant

July 17, 2023 | 12:55 pm

F

Ford Motor has announced significant price cuts for all versions of its electric F-150 Lightning pickup, with the cheapest version now starting at about $50,000, a roughly $10,000 cut. The price cuts are a result of Ford's efforts to boost production and lower costs for battery minerals. However, the production increase has not been smooth, with only 4,466 Lightnings sold in the second quarter due to a fire incident that led to a five-week production shutdown.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:50 pm

CYTO

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced the publication of detailed results from its clinical trial with Bentrio nasal spray in house dust mite allergic rhinitis. The study demonstrated statistically significant alleviation of nasal symptoms of allergic rhinitis. The trial enrolled 37 patients in Canada who underwent controlled allergen exposure. The results showed that Bentrio treatment reduced the increase in mean Total Nasal Symptom Score (TNSS) during the 3-hour exposure by 1.1 points vs. no treatment.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:47 pm

DDOG

IQV

OGN

SLB

On CNBC's 'Halftime Report Final Trades', four stocks were highlighted: IQVIA Holdings, Datadog, Organon & Co., and Schlumberger NV. IQVIA is expected to announce Q2 2023 financial results on Aug. 1, 2023. Datadog has a new integration monitoring OpenAI API usage patterns. Organon, with a 5.5% yield and 5 times earnings, announced the availability of HADLIMA™ in the U.S. Schlumberger is introducing an AI and machine learning platform in the oil space and secured a five-year contract from Petrobras.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 12:45 pm

AAPL

DigiTimes has reported that Apple's next-generation MacBook Pro will feature 3nm processors, according to industry sources.

Portfolio Pulse from Charles Gross

July 17, 2023 | 12:43 pm

MAR

MGM

Marriott International, Inc. (NASDAQ:MAR) and MGM Resorts International (NYSE:MGM) have announced an exclusive long-term strategic licensing agreement and the creation of MGM Collection with Marriott Bonvoy. The collection will launch in October 2023 and will include 17 of MGM's resorts, representing more than 40,000 rooms across the U.S. The agreement also includes a loyalty marketing agreement between Marriott and BetMGM. Members of both companies' loyalty programs will be able to link accounts and receive select benefits.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:42 pm

ABOS

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, a clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy for early Alzheimer's disease. The results showed that ACU193 was well-tolerated and demonstrated a significant reduction in amyloid plaque load. The company plans to discuss these results with regulators to assess the next steps for the clinical development of ACU193. Following the news, ABOS shares surged 97.40% in the premarket session.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 12:41 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has announced positive results from pharmacokinetic animal studies of its lead product candidate, EB-373, a psilocin-prodrug targeting anxiety disorders. The studies demonstrated oral bioavailability, rapid onset of action, systemic clearance, and a favorable side effect profile. The company plans to present thorough analyses of the studies at a future scientific conference.

Portfolio Pulse from Vuk Zdinjak

July 17, 2023 | 12:40 pm

LIXT

LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced that its lead clinical compound LB-100 has shown to enhance the effectiveness of immunotherapy and chemotherapy in preclinical studies. The studies, conducted in collaboration with the Netherlands Cancer Institute, revealed that LB-100 inhibits PP2A in colon cancer cells, leading to significant changes in mRNA processing. This results in the production of aberrant proteins that can be recognized by the immune system, making the cancer cells more sensitive to immunotherapy. The findings also suggest that LB-100 reduces the cancer cells' ability to deal with DNA damage, demonstrating synergy with radiotherapy and various chemotherapies.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:39 pm